Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Author:
- Parkinson Study Group CALM Cohort InvestigatorsPIParkinson Study Group CALM Cohort Investigators
Open Access
- 1 May 2009
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 66 (5) , 563-570
Abstract
Objective To compare the long-term outcomes of subjects initially treated with pramipexole dihydrochloride with those of subjects initially treated with levodopa in the Comparison of the Agonist Pramipexole With Levodopa on Motor Complications of Parkinson's Disease (CALM-PD) trial. Design Up to 2 years of open extended follow-up of the CALM-PD subjects. Setting Academic movement disorders clinics at 22 sites in the United States and Canada. Patients Patients with early Parkinson disease (N = 301) who required dopaminergic therapy to treat emerging disability were enrolled between October 1996 and August 1997, a subset of whom consented to extended follow-up until August 2003 (n = 222). Intervention Subjects were randomized to receive initial treatment with either pramipexole (n = 151) or levodopa (n = 150). Investigators were permitted to add open-label levodopa or other antiparkinsonian medications to treat ongoing or emerging disability. Main Outcome Measures The primary outcome variable was the time-weighted average of self-reported disability scores in the “on” and “off” states as measured by the Schwab and England Activities of Daily Living Scale at the final visit. Secondary outcomes included the Unified Parkinson's Disease Rating Scale score, the presence and severity of dopaminergic motor complications, quality-of-life scale scores, Geriatric Depression Scale score, Epworth Sleepiness Scale score, and adverse events. Results After a mean (SD) follow-up of 6.0 (0.2) years, mean (SD) self-reported weighted Schwab and England Activities of Daily Living Scale scores were similar in the initial pramipexole (79.9 [16.2]) and initial levodopa (82.5 [14.6]) groups (P = .19). Dopaminergic motor complications (wearing off, on-off effects, or dyskinesias) were more common in the initial levodopa group (68.4%) than in the initial pramipexole group (50.0%) (P = .002), although disabling dyskinesias were uncommon in both groups. The mean (SD) Epworth Sleepiness Scale score was significantly higher in the initial pramipexole group (11.3 [5.8]) than in the initial levodopa group (8.6 [4.7]) (P < .001). Mean (SD) changes from baseline in the total Unified Parkinson's Disease Rating Scale score did not significantly differ between the initial pramipexole (2.4 [17.4]) and initial levodopa (0.5 [17.1]) groups (P = .11). Conclusions The policies of initial pramipexole and initial levodopa use followed by open-label levodopa use resulted in similar self-reported disability 6 years after randomization. Persistent differences favoring initial pramipexole were seen in the rates of dopaminergic motor complications, with less severe somnolence favoring initial levodopa. Trial Registration clinicaltrials.gov Identifier: NCT00804479 Published online March 9, 2009 (doi:10.1001/archneurol.2009.32).Keywords
This publication has 10 references indexed in Scilit:
- Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PDNeurology, 2008
- Risk factors for somnolence, edema, and hallucinations in early Parkinson diseaseNeurology, 2007
- Ten-year follow-up of three different initial treatments in de-novo PDNeurology, 2001
- Pergolide-Induced Dyspnea, Bilateral Pleural Effusion and Peripheral EdemaRespiration, 2000
- Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control groupStatistics in Medicine, 1998
- Sleepiness in Different Situations Measured by the Epworth Sleepiness ScaleSLEEP, 1994
- Edema—An infrequently recognized complication of bromocriptine and other ergot dopaminergic drugsThe American Journal of Medicine, 1993
- Reliability and Factor Analysis of the Epworth Sleepiness ScaleSLEEP, 1992
- A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness ScaleSLEEP, 1991
- Development and validation of a geriatric depression screening scale: A preliminary reportJournal of Psychiatric Research, 1982